



Adopted	Rejected
---------	----------

## COMMITTEE REPORT

<b>YES:</b>	<b>11</b>
<b>NO:</b>	<b>0</b>

**MR. SPEAKER:**

*Your Committee on Public Health, to which was referred House Bill 1260, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill **be amended** as follows:*

- 1           Page 14, between lines 3 and 4, begin a new paragraph and insert:
- 2           "SECTION 20. IC 16-46-17-5, AS ADDED BY P.L.129-2023,
- 3           SECTION 2, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
- 4           JULY 1, 2024]: Sec. 5. (a) The following individuals serve as ex officio
- 5           voting members of the council:
- 6           (1) The director of the office of Medicaid policy and planning or
- 7           the director's designee.
- 8           (2) The commissioner of the department of insurance or the
- 9           commissioner's designee.
- 10          (3) The chief operating officer of the Indiana Minority Health
- 11          Coalition or the officer's designee.
- 12          **(4) The state health commissioner or the commissioner's**
- 13          **designee.**

- 1 (b) Before September 1, 2023, the governor shall appoint the  
2 following voting members:
- 3 (1) A representative from a research university in Indiana that  
4 receives grant funding for rare disease research.
  - 5 (2) A registered nurse or advanced practice registered nurse  
6 licensed under IC 25-23 with experience treating rare diseases.
  - 7 (3) A physician licensed under IC 25-22.5 with experience  
8 treating rare diseases.
  - 9 (4) A hospital administrator from a hospital licensed under  
10 IC 16-21 that provides care to individuals diagnosed with a rare  
11 disease.
  - 12 (5) Two (2) patients who have a rare disease.
  - 13 (6) A caregiver of an individual with a rare disease.
  - 14 (7) A representative of a rare disease patient organization that  
15 operates in Indiana.
  - 16 (8) A pharmacist with experience dispensing drugs used to treat  
17 rare diseases.
  - 18 (9) A representative of the biopharmaceutical industry.
  - 19 (10) A representative of a health carrier as defined by  
20 IC 27-1-46-3.
  - 21 (11) A member of the scientific community who is engaged in  
22 rare disease research, which may include a medical researcher  
23 with experience conducting research on rare diseases.
- 24 SECTION 21. IC 16-46-17-10, AS ADDED BY P.L.129-2023,  
25 SECTION 2, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE  
26 JULY 1, 2024]: Sec. 10. ~~Eight (8)~~ **Nine (9)** members of the council  
27 constitute a quorum. The affirmative vote of a majority of the quorum  
28 is required for the council to take any action."  
29 Renumber all SECTIONS consecutively.  
(Reference is to HB 1260 as introduced.)

**and when so amended that said bill do pass.**

Representative Barrett